SEC to discuss India’s first indigenously developed vaccine against cervical cancer
The vaccine is expected to be launched in the market before the end of 2022
The first indigenously developed quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer by the Serum Institute of India (SII) will be discussed by the Subject expert committee on Wednesday.
The application for market authorization of the qHPV vaccine was submitted to the DCGI on June 8 by Prakash Kumar Singh (director of government and regulatory affairs).
The application to the DCGI by Singh mentions the antibody response of the vaccine against HPV types in all dose and age groups.
The vaccine is expected to be launched in the market before the end of 2022, sources told ANI. The qHPV will be India’s first indigenously curated vaccine against cervical cancer.
To ensure its early availability in the country, the Pune-based Serum Institute of India has applied for market authorization after completing the phase 2/3 clinical trial with the support of the Department of Biotechnology.
IMF managing director Kristalina Georgieva has called for a ‘recalibration’ of China's tough ‘zero-COVID’ approach, which aims to isolate every case ‘exactly because of the impact it has on both people and the economy’
Mumbai is in the grips of a measles outbreak; the city has already recorded 12 deaths and 233 cases of the contagious viral disease. Health officials say that a disruption in the inoculation programme because of the COVID-19 pandemic as well as vaccine hesitancy has caused the surge in infections
US official says Chinese President Xi Jinping 'unwilling to accept Covid-19 vaccines' despite protests
She added that while the recent demonstrations in the country do not pose a threat to Communist Party rule, they may have an impact on his personal standing